Novel opportunities for treating complex neuropsychiatric and neurocognitive conditions based on recent developments with xanomeline

Bibliographic Details
Published in:	Frontiers in Psychiatry
Main Author:	Valentin A. Pavlov
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-05-01
Subjects:	schizophrenia xanomeline brain muscarinic receptors Alzheimer’s disease sepsis-associated encephalopathy inflammation
Online Access:	https://www.frontiersin.org/articles/10.3389/fpsyt.2025.1593341/full

Similar Items

Xanomeline/trospium-induced polyuria: A patient case report
by: Henry Leach, PharmD, BCPP, et al.
Published: (2025-10-01)

Is muscarinic receptor agonist effective and tolerant for schizophrenia?
by: Xiaonan Guo, et al.
Published: (2025-04-01)

Evaluating the Role and Efficacy of Cobenfy (Xanomeline and Trospium Chloride) in Schizophrenia Treatment - review
by: Michał Mazur, et al.
Published: (2025-04-01)

IUPHAR Review on muscarinic M1 and M4 receptors as drug treatment targets relevant to the molecular pathology of schizophrenia
by: Brian Dean
Published: (2024-12-01)

The New Horizon of Antipsychotics beyond the Classic Dopaminergic Hypothesis—The Case of the Xanomeline–Trospium Combination: A Systematic Review
by: Octavian Vasiliu, et al.
Published: (2024-05-01)

Does KarXT (xanomeline-trospium) represent a novel approach to schizophrenia management? A GRADE-assessed systematic review and meta-analysis of randomized controlled clinical trials
by: Hazem E. Mohammed, et al.
Published: (2025-03-01)

Early outpatient clinical experience with xanomeline and trospium chloride for schizophrenia: a case report
by: Maxwell Zachary Price, et al.
Published: (2025-06-01)

Novel Xanomeline-Containing Bitopic Ligands of Muscarinic Acetylcholine Receptors: Design, Synthesis and FRET Investigation
by: Carlo Matera, et al.
Published: (2023-03-01)

Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
by: Citrome L, et al.
Published: (2025-04-01)

Managing treatment-resistant schizophrenia following clozapine cessation: a case report of xanomeline–trospium and olanzapine combination therapy
by: Nils Sumegi Went, et al.
Published: (2025-10-01)

Treatment Of Schizophrenia With Cobenfy (KarXT): A Literature Review
by: Laura Kurczoba, et al.
Published: (2025-05-01)

The potential of muscarinic M1 and M4 receptor activators for the treatment of cognitive impairment associated with schizophrenia
by: Samantha E. Yohn, et al.
Published: (2024-10-01)

A New Era of Muscarinic Acetylcholine Receptor Modulators in Neurological Diseases, Cancer and Drug Abuse
by: Helena Tsimpili, et al.
Published: (2025-03-01)

Reduced phosphatidylcholine and phosphatidylethanolamine levels correlate with inflammatory activation in sepsis-associated encephalopathy
by: Mubing Qin, et al.
Published: (2025-08-01)

Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders
by: Chad R. Johnson, et al.
Published: (2022-02-01)

Postoperative sepsis-associated neurocognitive disorder: mechanisms, predictive strategies, and treatment approaches
by: Zijing Gao, et al.
Published: (2025-06-01)

Recent advances in the study of sepsis-induced depression
by: Yunyun Wang, et al.
Published: (2023-07-01)

Recent advances in the pathogenesis, diagnosis, and treatment of sepsis‐associated encephalopathy
by: Rui Wang, et al.
Published: (2024-06-01)

Markers of muscarinic deficit for individualized treatment in schizophrenia
by: Heiner Stuke, et al.
Published: (2023-01-01)

Amantadine reduces sepsis-induced brain injury via NLRP3/caspase-1 inflammasome activation
by: Pinar Karabacak, et al.
Published: (2025-05-01)

Therapeutic effects of orexin-A in sepsis-associated encephalopathy in mice
by: Jing Guo, et al.
Published: (2024-05-01)

Aspects of the formation of encephalopathy and myocardiopathy in sepsis
by: M. V. Petrova, et al.
Published: (2023-10-01)

The U-shaped relationship between serum osmolality and the risk of sepsis-associated delirium development: a retrospective study
by: Yipeng Fang, et al.
Published: (2025-06-01)

Muscarinic receptor agonists and positive allosteric modulators in animal models of psychosis: protocol for a systematic review and meta-analysis [version 2; peer review: 1 approved, 2 approved with reservations]
by: Spyridon Siafis, et al.
Published: (2025-01-01)

IUPHAR review: Moving beyond dopamine-based therapeutic strategies for schizophrenia
by: Paula M. Moran, et al.
Published: (2025-06-01)

Septic encephalopathy: does inflammation drive the brain crazy?
by: Felipe Dal-Pizzol, et al.
Published: (2014-09-01)

Editorial: Proteins and protein-complexes underlying mitochondrial structure-function and metabolism: implications in diseases
by: Mohammad Golam Sabbir, et al.
Published: (2024-03-01)

Pirenzepine Binding Sites in the Brain of the Honeybee <i>Apis mellifera</i>: Localization and Involvement in Non-Associative Learning
by: Chaïma Messikh, et al.
Published: (2022-09-01)

Wild/Woodland Mushroom Poisoning: The Experience of Bucharest Emergency Hospital-Retrospective Study of ER 2023–2024 Presentations
by: Bogdan Oprita, et al.
Published: (2025-08-01)

The Impact of Muscarinic Receptor Antagonists on Airway Inflammation: A Systematic Review
by: Calzetta L, et al.
Published: (2021-02-01)

Region-specific neuroprotective effects of meldonium pretreatment in two models of sepsis-associated encephalopathy
by: Aleksandra Ružičić, et al.
Published: (2025-04-01)

Mesenchymal stem cells and their conditioned medium as potential therapeutic strategies in managing comorbid anxiety in rat sepsis induced by cecal ligation and puncture
by: Mina Ranjbaran, et al.
Published: (2022-06-01)

The Anti-Aggregative Peptide KLVFF Mimics Aβ1-40 in the Modulation of Nicotinic Receptors: Implications for Peptide-Based Therapy
by: Hanna Trebesova, et al.
Published: (2022-09-01)

The Histaminergic System in Neuropsychiatric Disorders
by: Li Cheng, et al.
Published: (2021-09-01)

Selective effects of the APOE ε4 allele on presynaptic cholinergic markers in the neocortex of Alzheimer's disease
by: Mitchell K.P. Lai, et al.
Published: (2006-06-01)

EEG changes in critically ill patients with sepsis associated encephalopathy and its correlation with morbidity and mortality
by: Tamer A. Helmy, et al.
Published: (2024-12-01)

The novel schizophrenia subgroup “major neurocognitive psychosis” is validated as a distinct class through the analysis of immune-linked neurotoxicity biomarkers and neurocognitive deficits
by: Petar Popov, et al.
Published: (2024-10-01)

Muscarinic Receptors and Alzheimer’s Disease: New Perspectives and Mechanisms
by: Martina Monaco, et al.
Published: (2024-07-01)

Hydrogen alleviated cognitive impairment and blood‒brain barrier damage in sepsis-associated encephalopathy by regulating ABC efflux transporters in a PPARα-dependent manner
by: Yuanyuan Bai, et al.
Published: (2023-07-01)

Heart rate responses to a muscarinic agonist in rats with experimentally induced acute and subacute chagasic myocarditis
by: Argenis TORRES, et al.
Published: (2000-08-01)